Skip to main content

Cogent Biosciences, Inc 10-Q for FY2026 Q3

Cogent Biosciences, Inc. (COGT)

10-Q 2026-11-05 For: 2026-09-30
View Original
Added on November 06, 2026

About this 10-Q

Cogent Biosciences, Inc filed this 10-Q on November 5, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).

Cogent has three bezuclastinib NDAs pending FDA review, with PDUFA target dates November 30, 2026, December 30, 2026 and June 29, 2027. Cash, cash equivalents and marketable securities of $791.1 million were expected to fund operations into late 2028. AI summary

Headline figures

Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.

Net loss
$111.43M
compared with a net loss of $80.93M a year earlier
Diluted EPS
-$0.59
compared with -$0.50 a year earlier